Octreotide prophylaxis is not beneficial for biochemical activity and clinical severity of postoperative pancreatic fistula after pancreatic surgery

Digestive Surgery

Volumn 29, Issue 6, 2012, Pages 484-491

  Droeser, R A ^a,b   Jeanmonod, P ^a   Schuld, J ^a   Moussavian, M R ^a   Schilling, M K ^a   Kollmar, O ^a,b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

ISGPF criteria; Lipase activity; Octreotide; Pancreatic surgery; Postoperative pancreatic fistula

Indexed keywords

BIOLOGICAL MARKER; GASTROINTESTINAL AGENT; OCTREOTIDE; TRIACYLGLYCEROL LIPASE;

AGED; ARTICLE; DRUG ADMINISTRATION; EVALUATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; LENGTH OF STAY; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREAS FISTULA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; STATISTICS; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; KAPLAN-MEIER ESTIMATE; LENGTH OF STAY; LIPASE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OCTREOTIDE; PANCREATECTOMY; PANCREATIC FISTULA; PANCREATICODUODENECTOMY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84873388600     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000345874     Document Type: Article

References (29)

1. Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: the impact of eliminating so-cioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Diener MK, Fitzmaurice C, Schwarzer G, Seiler CM, Antes G, Knaebel HP, Buchler MW: Pyloruspreserving pancreaticoduode-nectomy (pp Whipple) versus pancreatico-duodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev 2011; 5:CD006053.
3. Kollmar O, Moussavian MR, Richter S, de Roi P, Maurer CA, Schilling MK: Prophylactic octreotide and delayed gastric emptying after pancreaticoduodenectomy: results of a prospective randomized double-blinded placebo-controlled trial. Eur J Surg Oncol 2008; 34: 868-875.
4. Halloran CM, Ghaneh P, Bosonnet L, Hartley MN, Sutton R, Neoptolemos JP: Complications of pancreatic cancer resection. Dig Surg 2002; 19: 138-146. (Pubitemid 34458062)
5. Kollmar O, Sperling J, Moussavian MR, Kubulus D, Richter S, Schilling MK: Delayed gastric emptying after pancreaticoduode-nectomy: influence of the orthotopic technique of reconstruction and intestinal moti-lin receptor expression. J Gastrointest Surg 2011; 15: 1158-1167.
6. Oettle H, Neuhaus P: Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs 2007; 67: 2293-2310. (Pubitemid 350071043)
7. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la FC, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M: FOLFIRINOX versus gemcitabine for meta-static pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
8. Diener MK, Seiler CM, Rossion I, Kleeff J, Glanemann M, Butturini G, Tomazic A, Bruns CJ, Busch OR, Farkas S, Belyaev O, Neoptolemos JP, Halloran C, Keck T, Niedergethmann M, Gellert K, Witzigmann H, Kollmar O, Langer P, Steger U, Neudecker J, Berrevoet F, Ganzera S, Heiss MM, Luntz SP, Bruckner T, Kieser M, Büchler MW: Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet 2011; 377: 1514-1522.
9. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, Neoptolemos J, Sarr M, Traverso W, Buchler M: Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005; 138: 8-13. (Pubitemid 40933766)
10. Büchler M, Friess H, Klempa I, Hermanek P, Sulkowski U, Becker H, Schafmayer A, Baca I, Lorenz D, Meister R: Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg 1992; 163: 125-130.
11. Berberat PO, Friess H, Uhl W, Büchler MW: The role of octreotide in the prevention of complications following pancreatic resection. Digestion 1999; 60(suppl 2):15-22. (Pubitemid 29178657)
12. Hesse UJ, De Decker C, Houtmeyers P, Demetter P, Ceelen W, Pattyn P, Troisi R, de Hemptinne B: Prospectively randomized trial using perioperative low dose octreotide to prevent organ related and general complications following pancreatic surger y and pancreatico-je-junostomy. Acta Chir Belg 2005; 105: 383-387. (Pubitemid 41284462)
13. Li-Ling J, Irving M: Somatostatin and oc-treotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br J Surg 2001; 88: 190-199. (Pubitemid 32142703)
14. Suc B, Msika S, Piccinini M, Fourtanier G, Hay JM, Flamant Y, Fingerhut A, Fagniez PL, Chipponi J: Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multicenter randomized controlled trial. Arch Surg 2004; 139: 288-294. (Pubitemid 38282670)
15. Pratt WB, Maithel SK, Vanounou T, Huang ZS, Callery MP, Vollmer CM Jr: Clinical and economic validation of the International Study Group of Pancreatic Fistula (ISGPF) classification scheme. Ann Surg 2007; 245: 443-451. (Pubitemid 46673141)
16. Frymerman AS, Schuld J, Ziehen P, Kollmar O, Justinger C, Merai M, Richter S, Schilling MK, Moussavian MR: Impact of postoperative pancreatic fistula on surgical outcome-the need for a classification-driven risk management. J Gastrointest Surg 2010; 14: 711-718.
17. Bassi C, Falconi M, Lombardi D, Briani G, Vesentini S, Camboni MG, Pederzoli P: Prophylaxis of complications after pancreatic surgery: results of a multicenter trial in Italy. Italian Study Group. Digestion 1994; 55(suppl 1):41-47. (Pubitemid 24020278)
18. Bassi C, Falconi M, Pederzoli P: Role of so-matostatin and somatostatin analogues in the treatment of gastrointestinal diseases: prevention of complications after pancreatic surgery. Gut 1994; 35:S20-S22. (Pubitemid 24157991)
19. Friess H, Klempa I, Hermanek P, Sulkowski U, Uhl W, Beger HG, Büchler MW: Prophylaxis of complications after pancreatic surgery: results of a multicenter trial in Germany. Digestion 1994; 55(suppl 1):35-40. (Pubitemid 24020277)
20. Friess H, Büchler MW: Efficacy of soma-tostatin and its analogues in pancreatic surgery and pancreatic disorders. Digestion 1996; 57(suppl 1):97-102. (Pubitemid 26183936)
21. Gouillat C: Somatostatin for the prevention of complications following pancreatoduode-nectomy. Digestion 1999; 60(suppl 3):59-63. (Pubitemid 29537548)
22. Montorsi M, Zago M, Mosca F, Capussotti L, Zotti E, Ribotta G, Fegiz G, Fissi S, Roviaro G, Peracchia A: Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial. Surgery 1995; 117: 26-31.
23. Graham JA, Johnson LB, Haddad N, Al-Kawas F, Carroll J, Jha R, Wong J, Maglaris D, Mertens S, Fishbein T: A prospective study of prophylactic long-acting octreotide in high-risk patients undergoing pancreaticoduode- nectomy. Am J Surg 2011; 201: 481-485.
24. Koti RS, Gurusamy KS, Fusai G, Davidson BR: Metaanalysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane review. HPB (Oxf) 2010; 12: 155-165.
25. Lai EC, Lau SH, Lau WY: Measures to prevent pancreatic fistula after pancreatoduo-denectomy: a comprehensive review. Arch Surg 2009; 144: 1074-1080.
26. Harris AG: Somatostatin and somatostatin analogues: pharmacokinetics and pharma-codynamic effects. Gut 1994; 35:S1-S4. (Pubitemid 24157987)
27. Carlsson PO, Jansson L: The long-acting so-matostatin analogue octreotide decreases pancreatic islet blood flow in rats. Pancreas 1994; 9: 361-364. (Pubitemid 24116723)
28. Conway DR, Djuricin G, Prinz RA: The ef-fec t of somatostatin a nalog ue (SMS 201-995) on pancreatic blood flow. Surgery 1988; 104: 1024-1030. (Pubitemid 19011982)
29. Turkcapar AG, Ersoz S, Gur U, Yerdel MA, Karaaslan A, Erden E, Kuterdem E: The effect of octreotid on bacterial translocation from the gut. An experimental study. Int Surg 1995; 80: 264-266. (Pubitemid 26017721)